Treatment Group |  | Rat IgG1 (µg/ml) |
---|
 | Seruma | CSFb |
---|
Noninduced | Â | Â | Â |
PBS | Â | <1, <1, <1 | <1 |
anti-IL-6 | d−1 | 33, >40, 33 | <1 |
 | d8 | 248, 254, 321 (274.3) | <1 |
anti-β-gal. | d−1 | 24, <1, <1 | <1 |
 | d8 | 280, 242, 204 (242) | <1 |
EAE | Â | Â | Â |
PBS | Â | <1, <1, <1 | <1 |
anti-IL-6 | d−1 | 1.1, 31, 5.2 (12.4) | 1 |
 | d8 | 243, 310, 391 (314.7) | 2.9 |
anti-β-gal. | d−1 | <1, 2, 1 | 1 |
 | d8 | 216, 192, 200 (202.7) | 3.4 |
- Rat IgG1 levels were determined by radial immunodiffusion on serum and CSF samples after administration of 1 mg of anti-IL-6 (20F3), anti-β-galactosidase (GL113), or PBS on either Day −1 (d−1) or Day 8 (d8) relative to active EAE induction. Animals were sampled at disease onset in the PBS group (Day 11–12).
- aSerum levels from individual mice are shown, the mean is given in parentheses where appropriate.
- bCSF levels are from pooled CSF (n = 3/group).